Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Journal Article

To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC).A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed.Of 277 patients (median age: 58years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C+Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7months, and median overall survival (OS) was 14.3 and 10.5months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n=19, OS of 20.4months), taxanes (n=55, OS of 20.2months), gemcitabine (n=106, OS of 14.1months), topotecan (n=43, OS of 13months), and cyclophosphamide (n=21, OS of 13months). There was no significant difference in toxicities between the C+Bev vs. Bev alone group.This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.

Full Text

Duke Authors

Cited Authors

  • Fuh, KC; Secord, AA; Bevis, KS; Huh, W; ElNaggar, A; Blansit, K; Previs, R; Tillmanns, T; Kapp, DS; Chan, JK

Published Date

  • December 2015

Published In

Volume / Issue

  • 139 / 3

Start / End Page

  • 413 - 418

PubMed ID

  • 26144600

Electronic International Standard Serial Number (EISSN)

  • 1095-6859

International Standard Serial Number (ISSN)

  • 0090-8258

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2015.06.041

Language

  • eng